Syndax Pharmaceuticals Inc
SNDX· Nasdaq
SNDXSyndax Pharmaceuticals Inc
Filed Feb 28, 2023 · 10-K · 59 days after period end · 0000950170-23-005079
derived · Computed from the longer spans the company filed.
| Metric | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020 | Q4 2019 |
|---|---|---|---|---|
| Revenue | — | $126.58M | $380.00K | $380.00K |
| Net Income | -$39.19M | $96.20M | -$20.42M | -$14.00M |
| EPS Diluted | — | — | -$0.44 | -$0.44 |
Syndax Pharmaceuticals Inc · CIK 1395937 · Engraved from SEC EDGAR
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
ended Dec 31, 2022 · filed Feb 28, 2023 · 59 d after period end
